Director/PDMR Shareholding

RNS Number : 0977S

AstraZeneca PLC

16 December 2016

 

16 December 2016 13:00

Transaction by a Person Discharging Managerial Responsibilities

Disclosure under Articles 19(3) and 19(6) of the EU Market Abuse Regulation

On 16 December 2016, Pascal Soriot, a Director of the Company, notified us that, on 16 December 2016, he ceased to be beneficially interested in 59,951 AstraZeneca PLC Ordinary Shares of $0.25 each as a result of a gift of those shares to family members for nil consideration.

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Pascal Soriot
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	AstraZeneca PLC
b)	LEI	Not applicable
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292
b)	Nature of the transaction	Gift of shares to family members for nil consideration
c)	Price(s) and volume(s)	Price(s) Volume(s) 0 59,951
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction
e)	Date of the transaction	16 December 2016
f)	Place of the transaction	London

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Enquiries
Neil Burrows	UK/Global	[phone]
Vanessa Rhodes	UK/Global	[phone]
Karen Birmingham	UK/Global	[phone]
Rob Skelding	UK/Global	[phone]
Jacob Lund	Sweden	[phone]
Michele Meixell	US	[phone]
Investor Relations
Thomas Kudsk Larsen		[phone]
Craig Marks	Finance, Fixed Income, M&A	[phone]
Henry Wheeler	Oncology	[phone]
Mitchell Chan	Oncology	[phone]
Lindsey Trickett	Cardiovascular & Metabolic Diseases	[phone]
Nick Stone	Respiratory	[phone]
Christer Gruvris	Autoimmunity, neuroscience & infection	[phone]
US toll free		[phone]

Adrian Kemp

Company Secretary, AstraZeneca PLC

-ENDS-

 

END

 

 

DSHUNVARNBAUAAA